636 related articles for article (PubMed ID: 25112173)
1. Clinical utility and validity of minoxidil response testing in androgenetic alopecia.
Goren A; Shapiro J; Roberts J; McCoy J; Desai N; Zarrab Z; Pietrzak A; Lotti T
Dermatol Ther; 2015; 28(1):13-6. PubMed ID: 25112173
[TBL] [Abstract][Full Text] [Related]
2. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia.
Roberts J; Desai N; McCoy J; Goren A
Dermatol Ther; 2014; 27(4):252-4. PubMed ID: 24773771
[TBL] [Abstract][Full Text] [Related]
3. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.
Goren A; Sharma A; Dhurat R; Shapiro J; Sinclair R; Situm M; Kovacevic M; Lukinovic Skudar V; Goldust M; Lotti T; McCoy J
Dermatol Ther; 2018 Nov; 31(6):e12741. PubMed ID: 30226287
[TBL] [Abstract][Full Text] [Related]
4. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia.
Goren A; Castano JA; McCoy J; Bermudez F; Lotti T
Dermatol Ther; 2014; 27(3):171-3. PubMed ID: 24283387
[TBL] [Abstract][Full Text] [Related]
5. Doppler laser imaging predicts response to topical minoxidil in the treatment of female pattern hair loss.
McCoy J; Kovacevic M; Situm M; Stanimirovic A; Bolanca Z; Goren A
J Biol Regul Homeost Agents; 2016; 30(1):131-4. PubMed ID: 27049083
[TBL] [Abstract][Full Text] [Related]
6. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients.
Ramos PM; Sinclair R; Miot HA; Goren A
Dermatol Ther; 2020 Jan; 33(1):e13195. PubMed ID: 31846181
[No Abstract] [Full Text] [Related]
7. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes.
Sharma A; Goren A; Dhurat R; Agrawal S; Sinclair R; Trüeb RM; Vañó-Galván S; Chen G; Tan Y; Kovacevic M; Situm M; McCoy J
Dermatol Ther; 2019 May; 32(3):e12915. PubMed ID: 30974011
[TBL] [Abstract][Full Text] [Related]
8. Topical minoxidil therapy for androgenetic alopecia. A 30-month study.
Koperski JA; Orenberg EK; Wilkinson DI
Arch Dermatol; 1987 Nov; 123(11):1483-7. PubMed ID: 3314717
[TBL] [Abstract][Full Text] [Related]
9. The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years.
Barbareschi M
G Ital Dermatol Venereol; 2018 Feb; 153(1):102-106. PubMed ID: 29319278
[TBL] [Abstract][Full Text] [Related]
10. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z
Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165
[TBL] [Abstract][Full Text] [Related]
11. Androgenetic alopecia and current methods of treatment.
Bienová M; Kucerová R; Fiurásková M; Hajdúch M; Koláŕ Z
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):5-8. PubMed ID: 15818439
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of the Clinical Efficacy of PRP-Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia.
Pakhomova EE; Smirnova IO
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899959
[TBL] [Abstract][Full Text] [Related]
13. Topical minoxidil: review of efficacy and safety.
Katz HI
Cutis; 1989 Jan; 43(1):94-8. PubMed ID: 2644080
[TBL] [Abstract][Full Text] [Related]
14. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
Gassmueller J; Hoffmann R; Webster A
Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
Blume-Peytavi U; Kunte C; Krisp A; Garcia Bartels N; Ellwanger U; Hoffmann R
J Dtsch Dermatol Ges; 2007 May; 5(5):391-5. PubMed ID: 17451383
[TBL] [Abstract][Full Text] [Related]
16. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity.
Goren A; Mccoy J; Kovacevic M; Situm M; Chitalia J; Dhurat R; Naccarato T; Lotti T
J Biol Regul Homeost Agents; 2018; 32(4):937-940. PubMed ID: 30043580
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.
Blume-Peytavi U; Issiakhem Z; Gautier S; Kottner J; Wigger-Alberti W; Fischer T; Hoffmann R; Tonner F; Bouroubi A; Voisard JJ
J Cosmet Dermatol; 2019 Feb; 18(1):215-220. PubMed ID: 29659116
[TBL] [Abstract][Full Text] [Related]
18. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
DeVillez RL; Jacobs JP; Szpunar CA; Warner ML
Arch Dermatol; 1994 Mar; 130(3):303-7. PubMed ID: 8129407
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women.
Tsuboi R; Tanaka T; Nishikawa T; Ueki R; Yamada H; Katsuoka K; Ogawa H; Takeda K
Eur J Dermatol; 2007; 17(1):37-44. PubMed ID: 17324826
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Olsen EA; Whiting D; Bergfeld W; Miller J; Hordinsky M; Wanser R; Zhang P; Kohut B
J Am Acad Dermatol; 2007 Nov; 57(5):767-74. PubMed ID: 17761356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
